Chromosomal translocations involving the human 12p13 band frequently aect the TEL gene, usually resulting in gene fusion between TEL and genes encoding proteins of various types. The most frequent 12p13 translocation is the t(12;21)(p13;q22), which recombines TEL with the AML1 gene on chromosome 21 and is frequently associated with deletion of the untranslocated TEL allele. Using antisera against dierent parts of TEL and against the AML1 proteins, we undertook Western blot and immuno¯uorescence analyses of leukemic samples with and without 12p13 abnormalities. In t(12;21) samples, TEL-AML1 was detected as several protein species in the nuclei, whereas the AML1-TEL protein, was inconsistently expressed. AML1 was found to be expressed but no normal TEL proteins were detected. A survey of the TEL proteins in a panel of human leukemic samples without t(12;21) revealed a variation in the ratio of TEL protein isoforms. We also analysed a leukemic cell line bearing a t(12;22)(p13;q11) that was found to aect the 5' untranslated (UT) region of TEL and to be associated with inactivation of the untranslocated TEL allele. No MN1-TEL fusion could be detected upon RT ± PCR analysis, in contrast to the previously investigated t(12;22). Strikingly, extremely low levels of apparently normal TEL proteins, expressed from the translocated allele, were detected by Western blot analysis. These results suggest that the level of TEL expression can be important for leukemogenesis.
Introduction
The TEL gene, located at chromosomal band 12p13, was ®rst isolated during the study of the t(5;12)(q33;p13) translocation (Golub et al., 1994) . Since then, it has been shown to be involved in a variety of translocations seen in human hematopoietic malignancies Golub et al., 1996b) .
The human TEL gene encodes a 452 aa protein that possesses an ETS DNA binding domain at its carboxyterminus. It shares with certain members of the Ets family an aminoterminal conserved region that has recently been shown, in the case of TEL, to mediate homotypic oligomerization of the protein (Golub et al., 1996a; Jousset et al., 1997) .
Normal TEL products are nuclear phosphoproteins that exist as several species. The ®rst two in-frame ATGs are active for translational initiation and both resulting proteins are post-translationally modi®ed . Both TEL proteins possess the ETS DNA binding domain and the TEL oligomerization domain. They dier in a 42 amino acid stretch that encompasses a Mitogen Activated Protein Kinase (MAPK) consensus site. This site is phosphorylated in vivo, suggesting dierential regulation of these two TEL species.
Various translocations involving the human 12p13 chromosomal band have been shown to aect the TEL gene Golub et al., 1996b) . Most of them result in transcription of fusion genes between TEL and a partner gene on the other chromosome. Strikingly, partner genes encode dierent sorts of proteins, such as transcription factors (AML1, MN1, EVI-1) (Buijs et al., 1995; Golub et al., 1995; Peeters et al., 1997a; Romana et al., 1995a) or protein kinases (PDGFRb, ABL, JAK2), (Golub et al., 1994; Lacronique et al., 1997; Papadopoulos et al., 1995; Peeters et al., 1997b) . In addition, the breakpoints of the dierent translocations within TEL are not clustered, further underscoring the dierential involvement of TEL in the leukemogenic process.
A search for deleted regions within the short arm of chromosome 12 identi®ed TEL as one of the putative target genes at 12p12-p13 in acute lymphoblastic leukemia (ALL) (CaveÂ et al., 1995; Stegmaier et al., 1996) . A tumor suppressor function was hypothesized for TEL, but no bi-allelic inactivation by point mutation within the remaining TEL allele was documented . In keeping with these data, monoallelic deletion of TEL was found to be closely associated with the t(12;21)(p13;q22) (Raynaud et al., 1996a) which occurs in 20 ± 30% of childhood B lineage ALL. This suggests that deletion of TEL would be meaningful only in association with a t(12;21).
Rearrangement and/or deletion of TEL are, however, observed in malignant samples without obvious 12p chromosomal abnormality, in particular without t(12;21) (unpublished results) (Andreasson et al., 1997) . This raises the possibility that the high frequency of t(12;21) could mask some less frequent events. Inactivation of TEL per se may be rare and would need investigation of a large number of samples to be identi®ed. In addition, several translocations involving TEL are not clearly associated with a predicted fusion protein (Raynaud et al., 1996b; Suto et al., 1997) , and are therefore suggestive of an inactivation of TEL.
Since most of the data have been obtained at the nucleic acid level, we investigated the TEL and AML1 derived polypeptides in human leukemic samples with or without t(12;21). This latter translocation results in the expression of a fused TEL-AML1 RNA, the reciprocal AML1-TEL RNA and the normal TEL RNA not being consistently detected in those samples. We used rabbit antisera raised against dierent parts of TEL and against AML1 to investigate the presence of each of the t(12;21) derived proteins. In addition, we report an example of deregulation of TEL expression in a human leukemic cell line, independently of a fusion protein.
Results

Detection of TEL-AML1 proteins in t(12;21) cells
Recombination between the TEL and AML1 genes, as a result of the t(12;21), is predicted to lead to the Figure 1a .
Competitive immunoprecipitation experiments of transiently transfected HeLa cells attested the specificity of the N-TEL antiserum (data not shown). Western blot comparison of endogenous and overexpressed TEL and TEL-AML1 proteins using the N-TEL antiserum is shown on the right hand panel of Figure 1b .
The N-TEL antiserum reacted with several protein species in the HL60 cellular extracts (Figure 1b ). These are identical to those detected using the C-TEL antiserum and have been shown to be due to alternative translational initiation and post-translational modi®cations .
The Reh cell line was investigated since it is known to possess a t(12;21) Rosenfeld et al., 1977) . No normal TEL proteins were detected (Figure 1b) , consistent with our previous data , but the N-TEL antiserum reacted with three abnormal protein species of 90 kDa, 96 kDa and 106 kDa. These species were not detected in a non t(12;21) sample (see the HL60 lane in Figure 1b ) and are of similar size to the major form detected in TEL-AML1 transfected HeLa cells (see lane 7 in Figure 1b ), suggesting that these proteins could correspond to the TEL-AML1 products. Since the AML1 antiserum is expected to react with the TEL-AML1 protein, the membrane was stripped and reprobed with this serum. High molecular weight species, identical to those detected with the N-TEL antibody, were detected in Reh cellular extracts but not in HL60 cells (see Figure 1b right hand panel). These data establish that TEL-AML1 protein is expressed in the Reh cell line as several protein species. The AML1 speci®c antiserum also deteced apparently normal AML1 polypeptides in the (12;21) samples (see Figure 1b and c) as well as in non t(12;21) cell lines ( Figure 1d ). They were abundantly expressed in the (12;21) samples and are therefore probably derived from the blast cells.
In order to compare the pattern of expression of TEL-AML1 proteins in the Reh cell line to that of other t(12;21) samples, cellular extracts from the human leukemic cell line UOC-B6 and from 10 acute lymphoblastic leukemia samples with a t(12;21) translocation were analysed by Western blot analysis using the N-TEL and the AML1 speci®c antisera ( Figure 1c and Table 1 ). In each sample, both antibodies detected a similar pattern of protein species between 90 and 106 kDa. The diversity of the TEL-AML1 proteins was similar to that observed in the Reh extract, ranging from three to ®ve bands. Taken together, these results show that the TEL-AML1 proteins are detected both with the N-TEL and the AML1 speci®c antisera as several species in all t(12;21) samples tested.
To establish the sub-cellular location of TEL-AML1, the N-TEL antiserum was used for immuno¯uorescence analyses of Reh cells. Since normal TEL proteins are absent from the Reh cell line , the N-TEL antiserum only detected the TEL-AML1 protein.
As shown in Figure 3d , TEL-AML1 proteins are detected as speckled nuclear dots, sparing the nucleoli. This immuno¯uorescence pro®le is similar to that of the normal TEL. A similar signal was also observed with the AML1 antiserum, which detects both AML1 and TEL-AML1 proteins ( Figure 3f ). Similar nuclear pattern was observed when leukemic samples were analysed by immuno¯uorescence, using either the N-TEL or the AML1 antisera (data not shown).
Detection of AML1 proteins
The AML1 speci®c antiserum reacted with protein species of 45 and 55 kDa in samples without obvious abnormalities at the AML1 locus (see for example HL60 sample Figure 1c and d) (Erickson et al., 1996; Meyers et al., 1995; Tanaka et al., 1995) . No AML1 related polypeptide was detected in the C33A extract, in keeping with the low expression of AML1 in this cell line (Meyers et al., 1995) (data not shown). The detection of several AML1 species can be interpreted as resulting from alternative splicing during transcription of AML1 and post-translational modi®cations of the AML1 proteins (Miyoshi et al., 1995; Tanaka et al., 1996) . In some samples, a lower molecular weight species was also detected (see for example lanes 24 and 25 Figure 1c ), whose size (30 kDa) is in agreement with the predicted size of the AML1A product (Meyers et al., 1995; Miyoshi et al., 1995) . Normal AML1 proteins were detected, in addition to TEL-AML1 species, in all t(12;21) samples tested (see Figure 1c and Table 1 ).
Detection of the AML1-TEL protein in t(12;21) cells
The reciprocal fusion product, AML1-TEL, is predicted to be expressed in one third of t(12;21) samples, as judged from RT ± PCR data. Western blot analysis using the C-TEL antiserum detected a protein species (Romana et al., 1995b) . 8Samples exhibiting apparently normal TEL protein by Western blotting demonstrated to originate from non-leukemic cells present in the sample TEL proteins in leukemias H Poirel et al of the expected size (17 kDa (Romana et al., 1995b) ) in UOC-B6, but not in the Reh cell line (see Figure 2a lanes 3 and 1, respectively). Identical results were obtained when UOC-B6 and Reh extracts were immunoprecipitated using the C-TEL antiserum prior to Western blot analysis (Figure 2a , lanes 4 and 2, respectively). Adsorption of the C-TEL antiserum by the GST-COOH-TEL immunogen abolished the immunoprecipitation of the 17 kDa polypeptide in the UOC-B6 extract, further con®rming the speci®city of the immunoprecipitated protein species (Figure 2a , lane 5). These results are consistant with the presence of the AML1-TEL transcript in UOC-B6 and its absence in Reh (Kim et al., 1996) , (data not shown). The AML1-TEL protein was also detected in three out of eight patients tested ( Figure 2b and Table 1) , consistent with previous RT ± PCR data when available (patients 6 and 8 (Romana et al., 1995b) ).
Absence of TEL expression in t(12;21) blast cells
Virtually all t(12;21) have been shown to be associated with inactivation by complete or partial deletion of the untranslocated TEL allele (Raynaud et al., 1996a) . We therefore used our antisera to investigate the t(12;21) samples for normal TEL protein expression. Western blot analysis with either the C-TEL or with the N-TEL antiserum did not reveal any normal TEL proteins in the two t(12;21) cell lines and in six out of the 10 samples with t(12;21) (Figure 2a and c) . Apparently normal TEL proteins could be detected in four samples. To establish the origin of this TEL expression, the C-TEL antiserum was used for immunocytochemistry or immuno¯uorescence analyses of these samples (data not shown). In these four cases, no speci®c signal was observed in the nuclei of the leukemic cells, but TEL was found to be expressed in the normal hematopoietic cells present in the sample. These results indicate that expression of normal TEL proteins in these samples is con®ned to normal hematopoietic cells present in the samples. As summarized In order to investigate the status of the TEL proteins in non t(12;21) samples, we analysed various leukemic samples by Western blot and immuno¯uorescence. All samples analysed by Western blot using the C-TEL and the N-TEL antisera, expressed normal sized TEL proteins, resolved in two doublets (Figure 4) . The larger doublet (57 ± 60 kDa) corresponds to posttranslational modi®cations of TEL proteins initiated at the ®rst methionine (M1) whereas the lower doublet (50 ± 52 kDa) to post translational modi®cation of TEL proteins initiated at the second in-frame methionine (M43) .
As judged from Western blot analysis using the C-TEL antiserum, the ratio of TEL-M1 and TEL-M43 isoforms was variable from sample to sample. Representative examples are shown in Figure 4 . In 10 out of 17 cases, the TEL-M1 and TEL-M43 were present at comparable levels (see for example Figure relationship between the M1/M43 ratio and the phenotype of the leukemic samples. The 17 leukemic samples were also investigated by immuno¯uorescence using the C-TEL, the N-TEL and the AML1 speci®c antisera ( Figure 3 and Table 2 ). The TEL proteins were always detected in the nuclei of the cells. The level of expression was, however, variable from cell to cell within a single sample for both cell line and leukemic samples, ranging from absence of signal to very strong¯uorescence (data not shown). In Nalm-6 cells, the C-TEL antiserum generated small speckled nuclear spots (Figure 3a) . Identical signals were observed using the N-TEL antiserum (Figure 3c ). In cells of the RPMI 8402 cell line, known to express more of the TEL-M43 than of the TEL-M1 isoforms Figure 4 lane 7) , TEL proteins appeared as larger nuclear dots. Three leukemic samples (9641, 94304 and 96270) exhibited a similar immuno¯uorescence pattern (data not shown). Interestingly, these samples exhibited the same biaised M1/ M43 ratio as RPMI 8402 (see Figure 4) . This pattern was not observed in samples with a more`classical' M1/M43 ratio.
Characterization of a t(12;22)(p13;q11) involving TEL, in a human leukemic cell line
Several examples of the t(12;22) translocations, which recombine TEL with the MN1 gene on chromosome 22, have been characterized (Buijs et al., 1995) . In order to analyse the t(12;22)(p13.2;q11.2) present in the MUTZ-3 cell line (MacLeod et al., 1996) , we investigated the involvement of the TEL locus by FISH analysis. Used as a probe on metaphase chromosomes, the 936E2 YAC, known to encompass the TEL gene, hybridized to the normal chromosome 12 and also to the derivative chromosomes 12 and 22. To further localize the chromosome 12 breakpoint, several cosmids covering dierent regions of the TEL gene (Baens et al., 1996) were used as probes. As shown Figure 5a , a cosmid speci®c for the ®rst exon of TEL, 179A6, generated three signals on the normal chromosome 12, the der(12) and the der(22) chromosomes. This result suggests that the chromosome 12 breakpoint lies within the sequences covered by the cosmid. In keeping with this, all cosmids encompassing the other coding exons (2 ± 8) of TEL generated a signal on the der(12) chromosome (data not shown) indicating that the TEL gene remained on der(12) and was structurally intact. Surprisingly, cosmids speci®c for exons 3 ± 5 did not generate any signal on the untranslocated chromosome 12, while the cosmids covering all the other coding exons of TEL did (data not shown). Taken together, our data show that the t(12;22) in the MUTZ-3 cell line aects the 5' part of the TEL locus and that the untranslocated TEL allele is partially deleted.
To investigate MN1 involvement in this t(12;22), we performed PCR analysis, starting from randomly primed cDNAs, using primers speci®c for the MN1-TEL fusion transcripts, based on previous reports (Buijs et al., 1995) . A MN1-TEL fusion transcript could be detected in RNA extracted from a bona ®de t(12;22) sample but not from MUTZ-3 RNA (data not shown), whereas other RNAs, including TEL could be detected in the MUTZ-3 template. This indicates that To determine if TEL is expressed in MUTZ-3, a TEL cDNA probe corresponding essentially to TEL exon 5 was used in Northern blot analysis of MUTZ-3 RNA (Figure 5b ). Normal TEL is expressed as one to three RNA species of 8.4 kb, 6 kb and 2.7 kb (Baens et al., 1996; Golub et al., 1994; Romana et al., 1995a) , which have been shown to derive from variation in the 3' UT regions and polyadenylation sites (Baens et al., 1996) . Only two TEL RNA species were detected in MUTZ-3 material, both of which were shorter than their normal counterparts. A probe corresponding to the entire open reading frame (ORF) of TEL reacted with the same RNA species in MUTZ-3 cells (data not shown), showing that TEL is transcribed only from the translocated chromosome 12.
In order to con®rm that the translocated TEL allele is transcribed and to further localize the chromosomal breakpoint with respect to the ®rst exon of TEL, two RT ± PCR experiments were performed. One with primers corresponding to the ®rst exon of TEL, spanning the ®rst ATG, and to the sequence in the TEL exon 5 and the second with primers corresponding to sequences in TEL exons 5 and 6. Since by FISH experiments, exon 5 is known to be deleted from the untranslocated TEL allele, these PCRs only allow detection of TEL transcription from the translocated allele. Using the MUTZ-3 random-primed cDNA that has been previously used for the MN1-TEL experiments and HL60 control cDNA, both RT ± PCR allowed ampli®cation of a speci®c TEL fragment of the expected size from control and from MUTZ-3 RNA (data not shown). Since TEL exon 1 is incorporated into a RNA which also contains exon 5, the chromosome 12 breakpoint in the MUTZ-3 cell line should lie 5' to the translation initiation site, in the TEL 5' UT region.
Taken together, our results show that TEL is weakly transcribed from the der(12) and should code for a normal sized TEL protein. To con®rm this point, MUTZ-3 extracts were analysed by Western blot analysis using our TEL speci®c antisera. As shown in Figure 5c , weak expression of normal sized TEL proteins, corresponding to TEL-M1 and TEL-M43 isoforms, were detected with the N-TEL antiserum. Furthermore, immuno¯uorescence analysis of MUTZ-3 cells localized the TEL proteins to the nucleus (data not shown).
Discussion
The TEL gene is known to be frequently involved in chromosomal abnormalities present in human malignant proliferations. The most frequent translocation aecting TEL to date is the t (12;21) , that recombines TEL with the AML1 gene on chromosome 21.
We used antisera speci®c of dierent domains of TEL to investigated human leukemic samples with or without obvious 12p13 abnormalities. The AML1-TEL chimeric transcript is detected in one third of the t(12;21) samples (Romana et al., 1995b) . This fusion RNA encodes an AML1-TEL chimeric protein, since it is detected in a t(12;21) cell line, UOC-B6, and in some, but not all, leukemic samples ( Figure 2b and Table 1 ). The AML1-TEL protein is not predicted to have an important role in the leukemic process, since it is not present in all cases. Nevertheless, since it Arrows indicate the location of the primers used for the RT ± PCR studies. *Design primers within exon 5 sequences, known to be deleted from the untranslocated TEL allele. Based on our FISH and RT ± PCR results, the breakpoint (shown by a large and white arrow) is located in the 5' untranslated region of TEL. The breakpoints previously characterized in the t(12;22) which result in a MN1 fusion are drawn with black arrowheads possesses the TEL ETS DNA binding domain, it remains to be determined if it could aect transcriptional regulation of TEL target genes, and, thereby play a role in the leukemic cells which express this chimeric protein.
The TEL-AML1 product was detected as several species (3 ± 5) in all t(12;21) samples tested, with sizes ranging from 90 ± 106 kDa. Detection of several protein species by Western blot analysis is not unexpected. Alternatively spliced mammalian AML1 transcripts have been described (Miyoshi et al., 1995) which encode AML1 proteins with various DNA binding anities and transcriptional activity. In addition, the AML1 proteins are known to be posttranslationally modi®ed (Tanaka et al., 1996) . Similarly, endogenous TEL proteins exist as multiple species, due, at least, to alternative translational initiation and post-translational modi®cations. It remains to be determined if all of the multiple species present in the nucleus of the t(12;21) cells are important for malignant proliferation. These TEL-AML1 proteins are presumed to exhibit a dominant negative eect with respect to the normal AML1 target genes (Hiebert et al., 1996) . Interestingly, Western blot analysis using the AML1 antiserum showed the presence of apparently normal AML1 proteins in all the t(12;21) samples. These AML1 polypeptides can be expressed from the normal AML1 allele, or from the proximal promoter, described upstream to the third exon of AML1 (Miyoshi et al., 1995) . If active, this promoter would allow the synthesis of AML1A and B isoforms. It is not known if AML1 is expressed during normal B cell dierentiation but the eect of the t(12;21) on the transcriptional regulation of AML1 could play a role in the malignant process.
In the present study, several leukemic cell lines were shown to express a 30 kDa AML1-related protein species whose size corresponds to AML1A (Figure 1d ). RT ± PCR experiments allowed us to speci®cally amplify the AML1A encoding RNA (data not shown) from RNA of cell lines that express the 30 kDa AML1 species (Reh, RPMI 8402) but not from cell lines that do not (for example Nalm-6; see Figure 1d ). A role for this AML1 protein in myeloid dierentiation has been postulated (Tanaka et al., 1995) and should be investigated in lymphoid dierentiation.
No normal TEL protein was detected in the blast cells of t(12;21) samples by analysis using both TEL antisera, re¯ecting the inactivation of the untranslocated TEL allele. Deletion or inactivation of the untranslocated TEL allele could be explained by the oligomerization properties of the amino terminal part of TEL. Interaction between normal TEL and TEL-AML1 proteins has been demonstrated in vitro and is postulated to impair the potential leukemogenic activity of TEL-AML1 in vivo (McLean et al., 1996) . It has been shown that, in some cases, deletion of the untranslocated TEL allele might be a secondary event in the leukemogenic process . Despite the small number of cases investigated in this study, our results suggest that the loss of expression of TEL is a frequent and early event in leukemogenesis.
In an attempt to detect additional examples of TEL alterations, we used the TEL antisera to perform Western blot and immuno¯uorescent analyses on 17 human leukemic samples without a t(12;21) translocation. TEL proteins were located in the nuclei of these cells and appeared to be of normal size by Western blot analysis. The balance of TEL-M1 and TEL-M43 isoforms was nevertheless variable among samples, with no obvious relationship to the phenotype of the various leukemias. These TEL isoforms dier in at least the presence of a MAPK consensus site which is phosphorylated in vivo. This site is conserved in murine TEL , suggesting that it could mediate signi®cant dierential regulation of the two TEL isoforms. It remains to be determined if the variable M1/M43 ratio observed in our leukemic samples has a function in the leukemic process or merely re¯ects variation in the stage of dierentiation.
We have molecularly investigated a t(12;22)(p13;q11) translocation in the MUTZ-3 human leukemic cell line. Unexpectedly, this translocation did not disrupt the TEL coding sequences, but aects the 5' UT region of the gene. In addition, no MN1-TEL fusion, as documented in several t(12;22) examples, could be detected in RT ± PCR experiments. Extremely weak expression of apparently normal TEL proteins was detected by Western blot analysis. These proteins are expressed from the translocated allele since the untranslocated TEL allele was shown by FISH to be deleted in exons 4 and 5.
The association of the t(12;22) and the partial deletion of the untranslocated TEL allele results in weak expression of TEL. This is likely to re¯ect inactivation of TEL. However, a chromosome 22 gene could be transcriptionally activated by the TEL promoters and this hypothesis is currently under investigation.
Other examples of TEL gene rearrangement have recently been reported that can result in loss of TEL function (Kim et al., 1996; Suto et al., 1997) . In addition, deletion of TEL can be observed without any associated 12p13 abnormality (unpublished results) (Andreasson et al., 1997) . Furthermore, the association of t(12;21) translocation and inactivation of the untranslocated TEL allele also results in complete loss of TEL activity. Taken together, these data suggest that the level of TEL expression is important in the leukemogenesis process.
Materials and methods
Expression vectors
The various TEL expression vectors have been described previously . AML-1B-pCMV vector was kindly provided by S Hiebert (Meyers et al., 1995) . The TEL-AML1 cDNA was constructed using PCR techniques, starting from TEL and AML1B cDNA and from a t(12;21) patient's cDNA, and shown by sequences analysis to be devoid of mutations.
In vitro transcription/translation was performed using the TNT kit, according to the manufacturer's speci®cations (Promega).
Antibodies
We used two dierent rabbit antisera raised against the aminoterminal part of TEL (N-TEL) or against the carboxyterminalpart of TEL (C-TEL) (see Figure 1a ) . Puri®cation of the GST-TEL fusion proteins and immunization of rabbits have been previously described . The polyclonal antiserum against AML1 has been reported (Erickson et al., 1996) .
Cell transfections
HeLa cells were transfected using the DMRIE-C Reagent following the manufacturer's instructions (Gibco ± BRL).
Immuno-analysis of malignant cells 10 7 cells were lysed in 100 ml of SDN buer (100 mM Tris-HCL pH 8, 150 mM NaCl, 5 mM EDTA, 0.5% Sodium desoxycholate, 0.5% Sodium Dodecyl Sulfate, 0.5% Nonidet P40) completed with protease (100 mg/ml phenylmethylsulfonyl¯uoride, 10 mg/ml leupeptin, 1% aprotinin) and phosphatase (20 mM b glycerophosphate, 50 mM orthovanadate, 10 mM NaF) inhibitors. After sonication and heat denaturation, 15 ± 40 ml of each sample was diluted in Laemmli buer and loaded on 10% denaturing acrylamide gels and blotted onto nitrocellulose ®lters. The quality of the transfer was evaluated by counter staining. The ®lters were then probed with a 1 : 10 000, 1 : 1000 or 1 : 100 dilution of N-TEL, C-TEL or AML1 rabbit antisera, respectively, in TBS-0.1%T (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Tween-20) 5% dry milk. They were revealed by enhanced chemiluminescence, following the manufacturer's instructions (Amersham).
For immuno¯uorescence studies, 10 5 cells were cytocentrifuged onto microslides, ®xed and permeabilized as previously described . They were incubated with a speci®c dilution of antiserum in the same buer as for Western blotting (TBS 0.1% Tween-20, 5% dry milk), 1 : 200, 1 : 600 or 1 : 50 of C-TEL, N-TEL or AML1 rabbit antisera, respectively. The C-TEL and the N-TEL antisera were preincubated with GST protein prior to utilization.
Cell lines and leukemic samples
Most of the leukemic cell lines have been widely described. Reh and UOCB6 are known to possess a t(12;21) translocation and to express a TEL-AML1 fusion transcript Kim et al., 1996) but no normal TEL transcript. Only UOC-B6 expresses the reciprocal AML1-TEL transcript. NB4 is human promyelocytic cell line (Lanotte et al., 1991) .
The MUTZ-3 cell line was established from a patient with acute myelomonocytic leukemia (AML FAB M4). Two TEL loci are present in the cells (MacLeod et al., 1996) .
Leukemic samples were as follows: 12 B lineage acute lymphoblastic leukemia samples (median age 4.5 years, range (2 ± 8)) at diagnosis, demonstrated to harbour a t(12;21)(p13;q22) translocation, as identi®ed by RT ± PCR; 32 randomly chosen samples without t(12;21) (19 ALL, 13 myeloid malignancies (15 adults and 17 children)). Both Western blot and immuno¯uorescence studies were available in 17/32 samples (13 ALL and four AML).
Fluorescent in situ hybridization (FISH)
FISH experiments were performed as previously described (Romana et al., 1994) . Probes used have been previously described (Baens et al., 1996) .
Nucleic acid methods
Northern blotting analysis was performed using 10 mg of total RNA and a probe corresponding to the ORF of TEL. Reverse transcriptase-polymerase chain reaction (RT ± PCR) was performed as previously described (Romana et al., 1995a) . The TEL primers were: SR13, B4, B8, B11 on TEL (Romana et al., 1995a,b) .
